Variable | |
---|---|
Female gender | 473 (64%) |
APOE ϵ4 carrier, (n = 718) | 493 (69%) |
Solitary living at baseline | 267 (36%) |
Anti-hypertensives/Cardiac therapy | 290 (40%) |
Anti-diabetics | 38 (5%) |
Lipid-lowering agents | 94 (13%) |
Estrogens | 52 (7%) |
NSAIDs/Acetylsalicylic acid | 221 (30%) |
Anti-depressants | 183 (25%) |
Anti-psychotics | 26 (4%) |
Anxiolytics/Sedatives/Hypnotics | 111 (15%) |
Variable | Mean ± standard deviation |
Estimated age at onset (years) | 72.3 ± 7.1 |
Estimated duration of AD at baseline (years) | 2.9 ± 2.0 |
Age at first assessment (years) | 75.2 ± 6.8 |
Education (years) | 9.6 ± 2.6 |
MMSE score at baseline | 23.4 ± 2.0 |
ADAS-cog score (0–70) at baseline | 17.5 ± 6.7 |
IADL score at baseline | 14.7 ± 5.0 |
Number of concomitant medications at baseline | 2.9 ± 2.4 |